Dacomitinib (Dacomitinib) new medical insurance price in 2024

Dacomitinib (Dacomitinib), trade name Vizimpro, is an innovative oral second-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) with irreversible inhibitory effects. This drug is specially designed to treat patients with metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. It is designed to overcome the resistance problems that arise during the treatment of first-generation EGFR-TKI, especially the common EGFR T790M mutation.

Thankfully, Dacomitinib is now on the market in China and has been successfully included in the medical insurance directory, bringing real financial burden relief to patients. At present, the specification of this medicine is 15 mg and 30 tablets, and the price is close to the people, about more than one thousand yuan. For specific price information and relevant policies on medical insurance reimbursement, patients are advised to consult the local hospital pharmacy to obtain the latest and most accurate information. In comparison, the price of the European version of Pfizer's original drug is significantly higher, about more than 20,000. In the foreign market, the price is relatively more affordable for generic drugs from Laos. Its specifications are 45mg and 30 tablets. The price is three times lower than the domestic price based on the previous multi-dimensional price, and its drug ingredients are basically the same as the original drugs, providing patients with more choices.

The mechanism of action of dacomitinib is to irreversibly bind and inhibit EGFR tyrosine kinase activity, effectively blocking the EGFR signaling pathway, thereby inhibiting the growth and proliferation of tumor cells. It has a strong inhibitory effect on a variety of EGFR mutations, including L858R and Exon 19 deletion mutations, which are common in NSCLC. Thanks to its irreversible binding mode, Dacomitinib exhibits more sustained efficacy in inhibiting EGFR activity, helping to extend patients' progression-free survival (PFS).

InARCHER 1050In clinical trials, dacomitinib (dacomitinib) demonstrated significant efficacy over the first-generation EGFR-TKIgefitinib. Trial data showed that the median progression-free survival in the dacomitinib (dacomitinib) treatment group reached 14.7 months, while the median progression-free survival in the gefitinib group was only 9.2 months. In addition, Dacomitinib also successfully extended the overall survival (OS) of patients. These encouraging results have led to Dacomitinib winning approval from the U.S. Food and Drug Administration (FDA) in 2018, making it the preferred first-line treatment for patients with metastatic NSCLC harboring EGFR mutations.